Quest for the right Drug
טיאוטפה מדומי 15מ"ג THIOTEPA MEDOMIE 15 MG (THIOTEPA)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה מרוכזת לעירוי : POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmaceutical particulars : מידע רוקחי
6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients None. 6.2 Incompatibilities Thiotepa Medomie is unstable in acid medium. This medicinal product must not be mixed with other medicinal products except those mentioned insection 6.6. 6.3 Shelf life Unopened vial The expiry date of the product is indicated on the packaging materials. After reconstitution Chemical and physical in-use stability after reconstitution has been demonstrated for 8 hours when stored at 2°C-8°C. After dilution Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2°C-8°C and for 4 hours when stored at 25°C. From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the above-mentioned conditions, unless the dilution has taken place in controlled and validated aseptic conditions. 6.4 Special precautions for storage Unopened vial Store in a refrigerator (2°C – 8°C). Do not freeze. After reconstitution and dilution For storage conditions of the reconstituted and diluted medicinal product, see section 6.3. 6.5 Nature and contents of container 16 Thiotepa Medomie-SPC-0322-V1 Type I clear glass vial with a bromo butyl double slotted rubber stopper, containing 15 mg thiotepa. Pack size of 1 vial. Type I clear glass vial with a bromo butyl igloo grey rubber stopper, containing 100 mg thiotepa. Pack size of 1 vial. 6.6 Special precautions for disposal Preparation of Thiotepa Medomie Procedures for proper handling and disposal of anticancer medicinal products must be considered. Alltransfer procedures require strict adherence to aseptic techniques, preferably employing a vertical laminar flow safety hood. As with other cytotoxic compounds, caution needs to be exercised in handling and preparation of Thiotepa Medomie solutions to avoid accidental contact with skin or mucous membranes. Topical reactions associated with accidental exposure to thiotepa may occur. In fact, the use of gloves is recommended inpreparing the solution for infusion. If thiotepa solution accidentally contacts the skin, the skin must be immediately and thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water. Reconstitution Thiotepa Medomie 15 mg Must be reconstituted with 1.5 ml of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection. Thiotepa Medomie 100 mg Must be reconstituted with 10 ml of sterile water for injection. Using a syringe fitted with a needle, aseptically withdraw 10 ml of sterile water for injection. Inject the content of the syringe into the vial through the rubber stopper. Remove the syringe and the needle and mix manually by repeated inversions. Only colourless solutions, without any particulate matter, must be used. Reconstituted solutions may occasionally show opalescence; such solutions can still be administered. Further dilution in the infusion bag The reconstituted solution is hypotonic and must be further diluted prior to administration with 500 mlsodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher than 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to obtain a final Thiotepa Medomie concentration between 0.5 and 1 mg/ml. Administration Thiotepa Medomie infusion solution should be inspected visually for particulate matter prior to administration. Solutions containing a precipitate should be discarded. Prior to and following each infusion, the indwelling catheter line should be flushed with approximately5 ml sodium chloride 9 mg/ml (0.9%) solution for injection. The infusion solution must be administered to patients using an infusion set equipped with a 0.2 µmin-line filter. Filtering does not alter solution potency. Disposal Thiotepa Medomie is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף